Biotest AG (BIESF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Biotest AG (BIESF) es una empresa del sector Healthcare valorada en 0. Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Biotest AG (BIESF) Resumen de Asistencia Médica y Tuberías
Biotest AG, a subsidiary of Grifols, S.A., operates in the biotechnology sector, developing and marketing biological medicines for hematology, clinical immunology, and intensive care. The company's focus on plasma-derived products and therapies for rare diseases positions it within a specialized segment of the global healthcare market, primarily serving Germany and international markets.
Tesis de Inversión
Biotest AG, as a subsidiary of Grifols, presents a focused investment opportunity within the specialized field of plasma-derived therapies. The company's established product portfolio in hematology, immunology, and intensive care provides a stable revenue base. Growth catalysts include the potential expansion of existing product lines and the introduction of new therapies. However, the company's negative profit margin of -7.1% and high P/E ratio of -36.18 indicate potential challenges in achieving profitability. The company's beta of 0.00 suggests low volatility relative to the market. The dividend yield is 0.13%.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $1.60 billion reflects Biotest AG's current valuation within the biotechnology sector.
- Negative P/E ratio of -36.18 indicates that the company is currently not profitable.
- Gross margin of 20.1% shows the percentage of revenue exceeding the cost of goods sold.
- Dividend yield of 0.13% provides a small return for investors.
- Biotest AG operates as a subsidiary of Grifols, S.A., providing financial backing and strategic direction.
Competidores y Pares
Fortalezas
- Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Operates as a subsidiary of Grifols, S.A.
Debilidades
- Negative profit margin.
- High P/E ratio.
- Dependence on plasma supply.
- Limited geographic diversification.
Catalizadores
- Upcoming: Clinical trial results for Trimodulin in community-acquired pneumonia and COVID-19.
- Upcoming: Regulatory approvals for new immunoglobulin therapies.
- Ongoing: Expansion into emerging markets in Asia and Latin America.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio.
- Ongoing: Advancements in plasma fractionation technology to improve efficiency.
Riesgos
- Potential: Competition from other biotechnology companies in the plasma-derived therapies market.
- Potential: Stringent regulatory requirements and compliance costs.
- Potential: Fluctuations in plasma supply and pricing.
- Ongoing: Patent expirations and generic competition.
- Ongoing: Negative profit margin and high P/E ratio.
Oportunidades de crecimiento
- Expansion of Trimodulin for Community-Acquired Pneumonia (CAP) and COVID-19: Trimodulin represents a significant growth opportunity for Biotest AG. The global market for CAP treatment is projected to reach billions of dollars, while the ongoing need for COVID-19 therapies further expands the potential market. Biotest's clinical trials and regulatory approvals will be critical milestones in capturing this market share. Success in these areas could significantly boost revenue and market position.
- Development of Novel Immunoglobulin Therapies: Biotest AG's focus on immunoglobulin therapies, such as Intratect and IgG Next Generation, presents a substantial growth opportunity. The global market for immunoglobulin therapies is expanding due to the increasing prevalence of immune deficiency disorders and autoimmune diseases. Biotest's research and development efforts in this area, coupled with successful clinical trials and regulatory approvals, could lead to the introduction of new and improved therapies, driving revenue growth.
- Geographic Expansion into Emerging Markets: Biotest AG has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These regions are experiencing growing demand for plasma-derived therapies due to increasing healthcare expenditure and improving access to healthcare services. By establishing partnerships, distribution networks, and regulatory approvals in these markets, Biotest can tap into new revenue streams and diversify its geographic footprint.
- Strategic Partnerships and Acquisitions: Biotest AG can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other biotechnology companies, research institutions, and healthcare providers can accelerate the development and commercialization of new therapies. Acquisitions of complementary businesses can broaden Biotest's product offerings and geographic reach, creating synergies and enhancing shareholder value.
- Advancements in Plasma Fractionation Technology: Investing in advanced plasma fractionation technologies can improve the efficiency and yield of plasma-derived products, reducing production costs and increasing profitability. By adopting innovative technologies such as membrane chromatography and continuous processing, Biotest can optimize its manufacturing processes and enhance its competitive advantage. These advancements can also lead to the development of new and improved plasma-derived therapies, further driving revenue growth.
Oportunidades
- Expansion of Trimodulin for CAP and COVID-19.
- Development of novel immunoglobulin therapies.
- Geographic expansion into emerging markets.
- Strategic partnerships and acquisitions.
Amenazas
- Competition from other biotechnology companies.
- Stringent regulatory requirements.
- Fluctuations in plasma supply and pricing.
- Patent expirations and generic competition.
Ventajas competitivas
- Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Proprietary manufacturing processes and technologies.
Acerca de BIESF
Biotest AG, founded in 1946 and headquartered in Dreieich, Germany, is a biotechnology company specializing in the development, manufacture, and sale of biological medicines. Originally known as Biotest Serum-Institut GmbH, the company changed its name in 1986. Its core business revolves around plasma-derived products used in hematology, clinical immunology, and intensive care medicine. Key products include treatments for hemophilia A and B (Haemoctin, Vihuma, and Haemonine), therapies for cytomegalovirus infections (Cytotect CP biotest), and prophylaxis against hepatitis B (Fovepta and Hepatect). Additionally, Biotest offers Intratect and IgG Next Generation for immune deficiencies and autoimmune diseases, Varitect for varicella zoster virus infections, and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides products like Albiomin and Biseko for blood volume restoration, Cofact for clotting factor deficiencies, Fibrinogen for congenital fibrinogen deficiency, Trimodulin for pneumonia and COVID-19, and Pentaglobin for bacterial infections. As of January 21, 2022, Biotest AG operates as a subsidiary of Grifols, S.A., a global healthcare company and a leading producer of plasma-derived medicines.
Qué hacen
- Develops biological medicines for hematology.
- Manufactures biological medicines for clinical immunology.
- Sells biological medicines for intensive care medicine.
- Offers treatments for hemophilia A and B.
- Provides therapies for cytomegalovirus infections.
- Offers prophylaxis against hepatitis B.
- Develops immunoglobulin therapies for immune deficiencies and autoimmune diseases.
- Provides products for blood volume restoration and clotting factor deficiencies.
Modelo de Negocio
- Develops and manufactures plasma-derived products.
- Sells biological medicines directly to hospitals and healthcare providers.
- Generates revenue through product sales in Germany and internationally.
- Focuses on therapies for rare diseases and specialized medical conditions.
Contexto de la Industria
Biotest AG operates within the biotechnology industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for plasma-derived therapies is driven by the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and growing demand for specialized treatments. Biotest's focus on hematology, immunology, and intensive care positions it within specific segments of this market. Competitors include other biotechnology companies specializing in plasma-derived products and therapies for rare diseases. The industry is subject to regulatory oversight by agencies such as the European Medicines Agency (EMA) and other international regulatory bodies.
Clientes Clave
- Hospitals and clinics.
- Healthcare providers.
- Patients with hematological disorders.
- Patients with immunological disorders.
- Patients in intensive care units.
Finanzas
Gráfico e información
Precio de la acción de Biotest AG (BIESF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BIESF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BIESF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BIESF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BIESF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Jorg Schuttrumpf
CEO
Jorg Schuttrumpf is the CEO of Biotest AG. Information regarding his detailed career history, education, and previous roles is not available in the provided context. As the CEO, he is responsible for the overall strategic direction and operational performance of the company, overseeing the development, manufacturing, and commercialization of biological medicines.
Historial: Information regarding Jorg Schuttrumpf's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided context. His role involves guiding Biotest AG in its focus on plasma-derived products and therapies for rare diseases, as well as navigating the competitive landscape of the biotechnology industry.
Información del mercado OTC de BIESF
The OTC Other tier, where BIESF trades, represents the lowest tier of the OTC market. Companies in this tier may not meet minimum financial standards and have limited reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with unproven business models, early-stage ventures, or those facing financial distress. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier, as the risk of fraud and manipulation is higher.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry and the risk of making investment decisions based on incomplete or unreliable data.
- Lower liquidity can lead to price volatility and difficulties in buying or selling shares at desired prices.
- The OTC Other tier has a higher risk of fraud and manipulation compared to major exchanges.
- Biotest AG's financial performance and prospects may be more uncertain due to the limited availability of information.
- The company's compliance with regulatory requirements may be less stringent compared to companies listed on major exchanges.
- Verify the company's registration and legal status in Germany.
- Obtain and review the company's financial statements, if available, from German regulatory filings or other sources.
- Assess the company's business model, products, and market position.
- Evaluate the company's management team and corporate governance practices.
- Research the company's history and track record, including any past legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks, including limited disclosure and liquidity.
- Consult with a financial advisor before making any investment decisions.
- Biotest AG is a subsidiary of Grifols, S.A., a reputable global healthcare company.
- The company has a long operating history, having been founded in 1946.
- Biotest AG develops and manufactures biological medicines for critical medical conditions.
- The company's products are subject to regulatory approvals and compliance.
- Biotest AG has a team of employees dedicated to research, development, and manufacturing.
Acciones de Biotest AG: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar BIESF?
Biotest AG (BIESF) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Specialized expertise in plasma-derived therapies.. Riesgo principal a monitorear: Potential: Competition from other biotechnology companies in the plasma-derived therapies market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BIESF?
BIESF actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BIESF?
Los precios de BIESF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BIESF?
La cobertura de analistas para BIESF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BIESF?
Las categorías de riesgo para BIESF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from other biotechnology companies in the plasma-derived therapies market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BIESF?
La relación P/E para BIESF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BIESF sobrevalorada o infravalorada?
Determinar si Biotest AG (BIESF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BIESF?
Biotest AG (BIESF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending for BIESF.
- OTC market data may be less reliable than data for exchange-listed stocks.